Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant

Natalizumab is used as a second-line treatment for multiple sclerosis (MS). Some reports have linked natalizumab to primary central nervous system lymphoma (PCNSL), although few have described its management. A 45-year-old woman with Balo’s Concentric Sclerosis presented dizziness, vertigo accompani...

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	Karine Moineau-Vallée, Justine Rinfret, My Hanh Luu Hoai, Valérie St-Louis, France Berthelet, Laurent Létourneau-Guillon, Émilie Lemieux-Blanchard, Alexandre Prat, Jean-Philippe Adam
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Subjects:	multiple sclerosis primary central nervous system lymphoma natalizumab autologous hematopoietic stem cell transplant
Online Access:	https://www.mdpi.com/1718-7729/28/1/22